版权说明 操作指南
首页 > 成果 > 详情

Insights into the involvement of long non-coding RNAs in doxorubicin resistance of cancer

认领
导出
Link by DOI
反馈
分享
QQ微信 微博
成果类型:
期刊论文
作者:
Zhang, Hai-Bo;Hu, Yang;Deng, Jun-Li;Fang, Guo-Ying;Zeng, Ying
通讯作者:
Fang, GY;Zeng, Y
作者机构:
[Fang, GY; Zhang, Hai-Bo; Fang, Guo-Ying] Hangzhou Womens Hosp, Hangzhou Matern & Child Hlth Care Hosp, Dept Pharm, Hangzhou, Peoples R China.
[Hu, Yang] Guangzhou Med Univ, Guangzhou Inst Resp Dis, Guangzhou, Peoples R China.
[Hu, Yang] Guangzhou Med Univ, Affiliated Hosp 1, China State Key Lab Resp Dis, Guangzhou, Peoples R China.
[Deng, Jun-Li] Southern Med Univ, Zhujiang Hosp, Dept Pharm, Guangzhou, Peoples R China.
[Zeng, Ying] Univ South China, Affiliated Changsha Cent Hosp, Hengyang Med Sch, Dept Pharm, Changsha, Peoples R China.
通讯机构:
[Fang, GY ] H
[Zeng, Y ] U
Hangzhou Womens Hosp, Hangzhou Matern & Child Hlth Care Hosp, Dept Pharm, Hangzhou, Peoples R China.
Univ South China, Affiliated Changsha Cent Hosp, Hengyang Med Sch, Dept Pharm, Changsha, Peoples R China.
语种:
英文
关键词:
cancer;doxorubicin;drug resistance;long non-coding RNA;molecular mechanisms
期刊:
Frontiers in Pharmacology
ISSN:
1663-9812
年:
2023
卷:
14
页码:
1243934
基金类别:
This research was funded by the National Natural Science Foundation of China (No. 82003870), Natural Science Foundation of Changsha (No. kq2014012), and the Key Research Project of Changsha Central Hospital (No. YNKY202204).
机构署名:
本校为通讯机构
院系归属:
药学与生物科学学院
摘要:
Doxorubicin is one of the most classical chemotherapeutic drugs for the treatment of cancer. However, resistance to the cytotoxic effects of doxorubicin in tumor cells remains a major obstacle. Aberrant expression of long non-coding RNAs (lncRNAs) has been associated with tumorigenesis and development via regulation of chromatin remodeling, transcription, and post-transcriptional processing. Emerging studies have also revealed that dysregulation of lncRNAs mediates the development of drug resistance through multiple molecules and pathways. In t...

反馈

验证码:
看不清楚,换一个
确定
取消

成果认领

标题:
用户 作者 通讯作者
请选择
请选择
确定
取消

提示

该栏目需要登录且有访问权限才可以访问

如果您有访问权限,请直接 登录访问

如果您没有访问权限,请联系管理员申请开通

管理员联系邮箱:yun@hnwdkj.com